Effects of Hemoglobin Variants and Chemically Modified Derivatives on Assays for Glycohemoglobin
Top Cited Papers
- 1 February 2001
- journal article
- review article
- Published by Oxford University Press (OUP) in Clinical Chemistry
- Vol. 47 (2) , 153-163
- https://doi.org/10.1093/clinchem/47.2.153
Abstract
Background: Glycohemoglobin (gHb), measured as hemoglobin (Hb) A1c or as total gHb, provides a common means for assessing long-term glycemic control in individuals with diabetes mellitus. Genetic variants and chemically modified derivatives of Hb can profoundly affect the accuracy of these measurements, although effects vary considerably among commercially available methods. The prevalence of genetic variants such as HbS, HbC, and HbE, and chemically modified derivatives such as carbamyl-Hb among patient populations undergoing testing is not insignificant. Clinical laboratories and sites responsible for point-of-care testing of gHb need to be aware of the interferences produced in assays by these Hbs. Approach: We conducted a review of the literature describing the effects of variant Hbs on gHb assay methods commonly used in clinical laboratories. Content: This review summarizes the documented effects of both common and uncommon Hb variants and derivatives on the measurement of gHb. Where known, we discuss mechanisms of interference on specific assays and methodologies. We specifically address effects of commonly encountered Hbs, such as carbamyl-Hb, HbS, HbC, HbE, and HbF, on assays that use cation-exchange chromatography, immunoassays, or boronate affinity methods for measuring gHb. Summary: A variety of patient- and laboratory-related factors can adversely affect the measurement of gHb in patients harboring Hb variants or derivatives. Identification of the variant or derivative Hb before or during testing may allow accurate measurement of gHb by the selection of a method unaffected by the given variant or derivative. However, laboratories should make available alternative, non-Hb-based methods for assessing long-term glycemic control in individuals with HbCC, HbSS, or HbSC disease, or with other underlying disorders where the concentration of gHb does not accurately reflect long-term glycemic control.This publication has 51 references indexed in Scilit:
- Evaluation of HbA1c determination methods in patients with hemoglobinopathies.Diabetes Care, 2000
- Effects of iron deficiency anemia on hemoglobin A1c in type 1 diabetes mellitusPediatrics International, 1999
- HbA1c determination in patients with hemoglobinopathies.Diabetes Care, 1999
- Hemoglobin Old Dominion/Burton-upon-Trent, β143 (H21) His→Tyr, Codon 143 CAC→TAC—a Variant With Altered Oxygen Affinity That Compromises Measurement of Glycated Hemoglobin in Diabetes Mellitus: Structure, Function, and DNA SequenceMayo Clinic Proceedings, 1998
- Identification and Genomic Analysis of Hemoglobin Long Island-Marseille in a Nondiabetic Subject of Italian OriginActa Haematologica, 1994
- A Diabetic Case of Hb Riyadh with a Low HbA1c Value.Internal Medicine, 1993
- Glycosylated haemoglobin (HbA1c) in iron‐ and vitamin B12 deficiencyJournal of Internal Medicine, 1990
- Hb Moriguchi or α2β297(FG4)His→Tyr Substitution at the α1-−β2InterfaceHemoglobin, 1989
- HB Fontainebleau [α21(B2)ALA→PRO], A new Silent Mutant HemoglobinHemoglobin, 1989
- Hemoglobin Hafnia: α2(β116 (G18)His→Gln)2; a new hemoglobin variant mistaken for glycated hemoglobinBiochimica et Biophysica Acta (BBA) - Protein Structure and Molecular Enzymology, 1988